Trimel Pharmaceuticals Corporation is a specialty pharmaceutical Company. The Company is engaged in the sale, distribution and development of products with a focus in men's health and women's health. The Company's products include Natesto, Estrace and Tefina. Natesto is a bioadhesive intranasal gel formulation of testosterone and is indicated for male hypogonadism. Natesto is available in United States. Estrace is an oral 17-beta estradiol tablet, which provides symptomatic relief of menopausal symptoms and also contributes to the prevention of osteoporosis in estrogen-deficiency. Tefina is an intranasal, low-dose gel formulation of testosterone and is indicated for female orgasmic disorder. Tefina has completed its Phase II clinical trials. The Company's holds a license for the development and marketing rights of its products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a unit-dose dry powder inhaler/nasal dispersion system, TriVair.